$ABT

ABBOTT LABORATORIES

CIK:0000001800|SEC Filings
v3.25.4
Consolidated Statement of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]      
Net Sales $ 44,328 $ 41,950 $ 40,109
Cost of products sold, excluding amortization of intangible assets 19,319 18,706 17,975
Amortization of intangible assets 1,682 1,878 1,966
Research and development 2,942 2,844 2,741
Selling, general and administrative 12,332 11,697 10,949
Total Operating Cost and Expenses 36,275 35,125 33,631
Operating Earnings 8,053 6,825 6,478
Interest expense 493 559 637
Interest income (308) (344) (385)
Net foreign exchange (gain) loss (50) (27) 41
Other (income) expense, net (548) (376) (479)
Earnings before Taxes 8,466 7,013 6,664
Taxes on Earnings 1,942 (6,389) 941
Net Earnings $ 6,524 $ 13,402 $ 5,723
Basic Earnings Per Common Share (in dollars per share) $ 3.73 $ 7.67 $ 3.28
Diluted Earnings Per Common Share (in dollars per share) $ 3.72 $ 7.64 $ 3.26
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) 1,741 1,740 1,740
Dilutive Common Stock Options (in shares) 7 8 9
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) 1,748 1,748 1,749
Outstanding Common Stock Options Having No Dilutive Effect (in shares) 1 7 5